Bio-Thera Solutions, Ltd. – FDA 483, Jan 17, 2025
An FDA inspection of Bio-Thera Solutions, Ltd. in Huangpu District, Guangzhou, revealed significant deficiencies in their drug substance and drug product manufacturing operations. The firm failed to establish and follow adequate procedures for preventing microbiological contamination, ensuring product quality through proper visual inspection and sampling, and maintaining data integrity. Furthermore, the Quality Unit's responsibilities and laboratory controls were found to be inadequate, raising concerns about the sterility and overall quality of their sterile drug products.
ID · 8b66a419-6663-4dfa-87f0-2fddfbf6cdda
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.